MREO vs. BEAM, SRPT, ARQT, IMCR, SDGR, EVO, OCUL, VERA, ETNB, and BHVN
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), Schrodinger (SDGR), Evotec (EVO), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), 89BIO (ETNB), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs. Its Competitors
Beam Therapeutics (NASDAQ:BEAM) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Beam Therapeutics presently has a consensus price target of $48.75, suggesting a potential upside of 145.22%. Mereo BioPharma Group has a consensus price target of $7.60, suggesting a potential upside of 164.81%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Beam Therapeutics.
In the previous week, Beam Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Beam Therapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.93 beat Beam Therapeutics' score of 0.93 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.
Mereo BioPharma Group has lower revenue, but higher earnings than Beam Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
Beam Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Mereo BioPharma Group has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Beam Therapeutics' return on equity of -44.24% beat Mereo BioPharma Group's return on equity.
99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Beam Therapeutics beats Mereo BioPharma Group on 9 of the 17 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 7/3/2025 by MarketBeat.com Staff
Free MREO Stock Alerts